3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
1520
Carcinoma, Non-Small-Cell Lung
754
Breast Neoplasms
572
Neoplasm Metastasis
529
Colorectal Neoplasms
445
Melanoma
391
Leukemia, Myeloid, Acute
371
Multiple Myeloma
363
Ovarian Neoplasms
352
Recurrence
336
Lymphoma
334
Advanced Solid Tumors
324
Lymphoma, Non-Hodgkin
314
Prostatic Neoplasms
300
Pancreatic Neoplasms
285
Advanced Solid Tumor
240
Stomach Neoplasms
232
Carcinoma, Renal Cell
225
Squamous Cell Carcinoma of Head and Neck
210
Lung Neoplasms
210
Solid Tumor
204
Leukemia, Lymphocytic, Chronic, B-Cell
198
Triple Negative Breast Neoplasms
183
Solid Tumors
182
Carcinoma, Hepatocellular
164
Hematologic Neoplasms
155
Head and Neck Neoplasms
152
Lymphoma, Large B-Cell, Diffuse
148
Lymphoma, Follicular
146
Glioblastoma
145
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
INDUSTRY
×
Muscle Invasive Bladder Cancer
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled